Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07029217 · ClinicalTrials.gov registry record · Phase 3
A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas
A Phase 3 study of Follicular Lymphoma and Marginal Zone Lymphoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 375
- Enrollment target
- 7
- Study locations
NCT07029217 is a Phase 3 study of Follicular Lymphoma and Marginal Zone Lymphoma that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 375 participants, above the 131-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (186% higher). The trial reports 7 study locations across 2 states.
The verdict
NCT07029217, a Phase 3 study of Follicular Lymphoma and Marginal Zone Lymphoma, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 375 participants
- Enrollment target
- 7
- Study locations
Study Summary
The researchers are doing this study to find out whether a very low dose of radiation therapy (VLDRT) is an effective treatment for people with follicular lymphoma (FL) or marginal zone lymphoma (MZL) and works as well as the standard dose of radiation therapy. The researchers will see if VLDRT works against cancer in the area that is currently affected by cancer and if the therapy prevents new spots of lymphoma from developing. The researchers will also compare VLDRT with the standard dose of radiation therapy to see if VLDRT causes fewer side effects. Radiation therapy uses beams of intense energy to kill cancer cells. Standard doses of radiation therapy can cause short- and long-term side effects. Researchers think VLDRT may be as effective as standard doses, and, because VLDRT uses less radiation, researchers think VLDRT may cause fewer side effects than standard doses.
Conditions Studied
Interventions
- RADIATION Radiation (Standard)
- RADIATION Radiation (Very low dose)
Study Locations (7)
New York
- Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (All Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (All Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (All Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 375 participants |
| Start Date | 2025-06-09 |
| Est. Completion | 2028-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07029217
The ClinicalTrials.gov registry entry for NCT07029217 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 375 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 131-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (186% higher). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Follicular Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Radiation (Standard) is the first listed.
NCT07029217 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT07029217 about?
NCT07029217 is a clinical study titled "A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas". The researchers are doing this study to find out whether a very low dose of radiation therapy (VLDRT) is an effective treatment for people with follicular lymphoma (FL) or marginal zone lymphoma (MZL) and works as well as the standard dose of radiation therapy. The researchers will see if VLDRT work...
What is the current status of trial NCT07029217?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 375 participants. The study started on 2025-06-09. Estimated completion is 2028-06.
What conditions does trial NCT07029217 study?
This clinical trial studies the following conditions: Follicular Lymphoma, Marginal Zone Lymphoma.
What interventions are being tested in trial NCT07029217?
The interventions under investigation include: Radiation (Standard) (RADIATION), Radiation (Very low dose) (RADIATION).
Who is sponsoring clinical trial NCT07029217?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07029217 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Follicular Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Long-term Extension Study of PCI-32765 (Ibrutinib)
RECRUITING · Phase 3
-
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
RECRUITING · Phase 3
-
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
RECRUITING · Phase 3
-
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
ACTIVE NOT RECRUITING · Phase 3
-
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
COMPLETED · Phase 3
-
A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.